.jpg)
Poster
AACR 2024 Poster
Systematic Analysis of Gene Mutations and Therapeutic Efficacy via Ex vivo Hematological VitroScreen Platform
Summary
Acute myeloid leukemia (AML) is the most common hematological malignancy, with FLT3 mutations emerging as a key therapeutic target. Other mutations like TP53, TET2, and the overexpression of drug-resistance genes also influence treatment sensitivity. The poster highlights champions' hematological VitroScreen platform offering a cost-effective solution for screening new FLT3 inhibitors and other novel anti-cancer agents for AML. Additionally, the Lumin platform integrates multi-omic data from Champions' tumor models with public datasets, enabling efficient model selection and data interpretation.
The ex vivo hematological VitroScreen platform offers an efficient and cost-effective method for testing drug performance.
Our study findings demonstrate that FLT3 mutations enhance the sensitivity to FLT3 inhibitors, while TP53 mutations and S100A8 overexpression decrease sensitivity to standard-of-care treatments, consistent with clinical trial observations.
The integration of the Lumin bioinformatics platform with the ex vivo hematological VitroScreen platform provides a powerful tool for drug development.